Population
AT1 angiotensin receptor model
Design
Preclinical
Authors
Loading...
No immediate change to AT1 therapies warranted; leaves open translation of receptor interactions to human drug design.
The docking of Arg2 of angiotensin II with Asp281 of the AT1 receptor is essential for full agonism, providing a structural basis for redesigning non-peptide AT1 receptor agonists.
Feng et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: